$XNCR News

How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit

RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20

Wedbush Maintains Outperform on Xencor, Raises Price Target to $30

Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Xencor (NASDAQ:XNCR) Beats Q2 Estimates on Royalty Settlement and Milestone Payment

Xencor Reports Second Quarter 2026 Financial Results

Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate

Wedbush Reiterates Outperform on Xencor, Maintains $26 Price Target

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27

Xencor: Bullish On Their Increasingly In-House Pipeline

Truist Securities Maintains Buy on Xencor, Lowers Price Target to $27

Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution

Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat

Xencor Reports First Quarter 2026 Financial Results

Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026